Identification of Specific Molecular Signatures in Pediatric, Adolescent, and Young Adult Rhabdomyosarcoma Through Spatial Proteome Analysis Using Mass Spectrometry

Launched by LILLE UNIVERSITY · Apr 4, 2025

Keywords

ClinConnect Summary

This clinical trial is studying rhabdomyosarcoma, a type of cancer that affects children and young adults. Researchers are using advanced techniques to analyze small samples of tumor tissue collected from patients. Their goal is to identify specific molecular signatures, which are unique patterns found in the tumors. These patterns can help doctors understand different tumor types, how they may respond to treatment, and why some patients may have better or worse outcomes.

To participate, individuals must be between 0 and 25 years old and have a confirmed diagnosis of rhabdomyosarcoma. They should have received care at the Oscar Lambret Center between January 2005 and November 2024 and must agree to allow researchers to use their existing data and tumor samples for this study. Participants will not need to undergo any new treatments or procedures; instead, the study will use samples that have already been collected during their regular care. This research could provide valuable insights into rhabdomyosarcoma and potentially improve future treatments for patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age between 0 and 25 years at the time of initial diagnosis
• • Diagnosis of rhabdomyosarcoma confirmed histologically
• • Care at the Oscar Lambret Center between January 2005 and November 2024
• • No objection to the re-use of data and biological samples collected as part of care for research activities.
• Exclusion Criteria:
• • Unavailability of biological sample in FFPE from biopsy and/or surgical specimen for diagnosis at Centre Oscar Lambret;
• • Patient under guardianship or trusteeship.